Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir

C. Ippoliti, A. Morgan, D. Warkentin, K. Van Besien, R. Mehra, I. Khouri, S. Giralt, J. Gajewski, R. Champlin, B. Andersson, D. Przepiorka

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Cytomegalovirus (CMV) disease can be prevented by administration of ganciclovir prophylactically post-transplant. However, up to 30% of patients discontinue use of ganciclovir as a result of profound neutropenia and may subsequently develop CMV infections while unprotected. To prevent reactivation of CMV, we administered foscarnet to 39 adults unable to receive ganciclovir due to delayed engraftment or ganciclovir-induced neutropenia. Twenty-four (62%) of the patients had received T cell-depleted marrow transplants. Foscarnet sodium 60 mg/kg i.v. daily was continued until the neutropenia resolved, at which time ganciclovir was resumed. CMV prophylaxis commenced at a median of 28 days following transplantation. Median time to initiation of foscarnet was day 60 post-transplant, and the median duration of treatment was 22 days. Foscarnet was well-tolerated. Six (15%) patients had CMV detected while receiving prophylaxis, and CMV-related mortality was 5%. Foscarnet is a safe and effective agent for prevention of CMV disease in allogeneic transplant recipients unable to receive ganciclovir.

Original languageEnglish (US)
Pages (from-to)491-495
Number of pages5
JournalBone marrow transplantation
Volume20
Issue number6
DOIs
StatePublished - Sep 2 1997
Externally publishedYes

Keywords

  • Allogeneic
  • BMT
  • Cytomegalovirus
  • Foscarnet
  • Ganciclovir

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir'. Together they form a unique fingerprint.

Cite this